Abstract
Current prognostic markers cannot adequately predict the clinical outcome of breast cancer patients. Therefore, additional biomarkers need to be included in routine immune panels. FOXA1 was a significant predictor of favorable outcome in primary breast cancer, while Nestin expression is preferentially found in triple-negative tumors with increased rate of nodal metastases, and reduced survival. No studies have investigated the prognostic value of FOXA1 and Nestin expression in breast cancer metastases. Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression. Cox regression analysis assessed the prognostic value of FOXA1 and Nestin expression. In breast cancer metastases, FOXA1 expression was associated with Nestin-negativity, GATA3-positivity, ER-positivity, HER2-positivity and non-triple-negative status (P < 0.05). In contrast, Nestin expression was associated with FOXA1-negative, GATA3-negative, ER-negative, and triple-negative metastases (P < 0.05). Univariate Cox regression analysis showed FOXA1 expression was predictive of overall survival (OS, P = 0.00048) and metastasis-free survival (DMFS, P = 0.0011), as well as, dista...Continue Reading
References
Nov 27, 2007·Journal of Clinical Pathology·M A ThoratS Badve
Jun 10, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hany Onsy HabashyIan O Ellis
Jul 22, 2008·Journal of Clinical Pathology·S ParryJ S Reis-Filho
Mar 6, 2009·Expert Reviews in Molecular Medicine·Harikrishna Nakshatri, Sunil Badve
Jun 25, 2009·Breast Cancer Research : BCR·André AlbergariaFernando Schmitt
Dec 1, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Foluso O AdemuyiwaSunil Badve
Dec 15, 2010·Genome Research·Christiane M RobbinsJohn D Carpten
Apr 20, 2011·Breast Cancer Research and Treatment·Rutika J MehtaSunil Badve
Sep 22, 2011·The EMBO Journal·Michael A AugelloKaren E Knudsen
Feb 3, 2012·European Journal of Histochemistry : EJH·F PirasP Sirigu
Apr 6, 2012·Hormones & Cancer·Nobuhiro IjichiSatoshi Inoue
May 23, 2012·Nature Genetics·Christopher E BarbieriLevi A Garraway
Jun 23, 2012·Nature·Catherine S GrassoScott A Tomlins
Feb 20, 2013·Frontiers in Oncology·Jessica L L RobinsonJason S Carroll
Jun 19, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Mai KawaseHiroko Yamashita
Jan 15, 2014·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yuichi HisamatsuYoshihiko Maehara
Feb 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Qing HuJin-Hai Tang
Nov 26, 2014·British Journal of Cancer·Y HorimotoM Saito
Apr 2, 2016·Science Advances·Gaihua ZhangZhaoyu Li
Feb 13, 2017·Biochemical and Biophysical Research Communications·Wen FengChunhui Song
Mar 9, 2017·The Journal of Biological Chemistry·Noritaka YamaguchiNaoto Yamaguchi
Apr 26, 2017·Scientific Reports·Kristi KrügerLars A Akslen
May 12, 2017·Ecancermedicalscience·Consuelo Morigi
Jun 1, 2017·Breast Care·Michael GnantChristoph Thomssen
Jun 29, 2017·International Journal of Oncology·Aleksandra NowakPiotr Dziegiel
Jul 14, 2017·The Breast Journal·Shahin De LaraAnikó Kovács
Sep 5, 2017·Biological & Pharmaceutical Bulletin·Erina AnzaiNoritaka Yamaguchi
Nov 22, 2017·Breast Cancer Research and Treatment·Karama AslehTorsten O Nielsen
Jun 9, 2018·British Journal of Cancer·Séverine GuiuWilliam Jacot
Jul 5, 2018·Molecular Oncology·Willemijne SchrijverWilbert Zwart